Jasmohan S Bajaj1, Andres Duarte-Rojo2, Jesse J Xie2, Chathur Acharya3, James B Wade4, Carlos Robles5, Leroy R Thacker4, Christopher Flud2, Andrew Fagan3, Mauricio Garcia-Saenz-de-Sicilia2, Melanie B White3, Megan Kelly5, Vy Nguyen5, Edith A Gavis3, Hugo E Vargas5. 1. Virginia Commonwealth University Medical Center, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia; Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia. Electronic address: jasmohan.bajaj@vcuhealth.org. 2. University of Arkansas School of Medical Sciences, Little Rock, Arkansas. 3. Virginia Commonwealth University Medical Center, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia; Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia. 4. Virginia Commonwealth University Medical Center, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia. 5. Mayo Clinic, Phoenix, Arizona.
Abstract
BACKGROUND & AIMS: Patients with cirrhosis are growing older. The overlap between minimal hepatic encephalopathy (MHE) and predementia mild cognitive impairment (MCI) could affect quality of life (QOL). We investigated the performance of elderly patients with cirrhosis on tests for MHE and MCI and their effects on QOL. METHODS: We recruited outpatients with cirrhosis (n = 109) and without cirrhosis (controls, n = 100), 65 years or older, at 4 centers (derivation cohort). All study participants were assessed for psychometric hepatic encephalopathy score (PHES), EncephalApp score, and QOL. MCI was tested in patients with cirrhosis using the repeatable battery for assessment of neuropsychological status and assigned to the following groups: unimpaired, MCI only, MHE only, and MCI+MHE. We created adjusted norms to detect MHE using PHES and EncephalApp scores from the controls. Findings were validated using data from a separate cohort of 77 patients with cirrhosis (mean age, 69.49 ± 4.36 y; 72% men) at the same study sites. RESULTS: Controls were older but were more educated, performed better cognitively, and had better QOL. Among patients with cirrhosis, age, education, model for end-stage liver disease score, EncephalApp score, and QOL were similar, but PHES and repeatable battery for assessment of neuropsychological status differed among sites. In the derivation cohort, the presence of MHE, with or without MCI, was associated with poor QOL, which was lowest in the MCI+MHE group. When we adjusted for age, sex, and education, 49% of patients with cirrhosis had MHE based on the EncephalApp and 8% had MHE based on the PHES. A similar pattern (49% MHE based on EncephalApp and 6% MHE based on PHES) was found in a validation cohort. CONCLUSIONS: In a multicenter study of patients with cirrhosis (>65 y) and controls, the presence of MHE, regardless of MCI, was associated with poor cognition and QOL. We created adjusted norms that defined the high sensitivity of EncephalApp for the detection of MHE in older individuals and validated it in a separate cohort.
BACKGROUND & AIMS:Patients with cirrhosis are growing older. The overlap between minimal hepatic encephalopathy (MHE) and predementia mild cognitive impairment (MCI) could affect quality of life (QOL). We investigated the performance of elderly patients with cirrhosis on tests for MHE and MCI and their effects on QOL. METHODS: We recruited outpatients with cirrhosis (n = 109) and without cirrhosis (controls, n = 100), 65 years or older, at 4 centers (derivation cohort). All study participants were assessed for psychometric hepatic encephalopathy score (PHES), EncephalApp score, and QOL. MCI was tested in patients with cirrhosis using the repeatable battery for assessment of neuropsychological status and assigned to the following groups: unimpaired, MCI only, MHE only, and MCI+MHE. We created adjusted norms to detect MHE using PHES and EncephalApp scores from the controls. Findings were validated using data from a separate cohort of 77 patients with cirrhosis (mean age, 69.49 ± 4.36 y; 72% men) at the same study sites. RESULTS: Controls were older but were more educated, performed better cognitively, and had better QOL. Among patients with cirrhosis, age, education, model for end-stage liver disease score, EncephalApp score, and QOL were similar, but PHES and repeatable battery for assessment of neuropsychological status differed among sites. In the derivation cohort, the presence of MHE, with or without MCI, was associated with poor QOL, which was lowest in the MCI+MHE group. When we adjusted for age, sex, and education, 49% of patients with cirrhosis had MHE based on the EncephalApp and 8% had MHE based on the PHES. A similar pattern (49% MHE based on EncephalApp and 6% MHE based on PHES) was found in a validation cohort. CONCLUSIONS: In a multicenter study of patients with cirrhosis (>65 y) and controls, the presence of MHE, regardless of MCI, was associated with poor cognition and QOL. We created adjusted norms that defined the high sensitivity of EncephalApp for the detection of MHE in older individuals and validated it in a separate cohort.
Authors: Hendrik Vilstrup; Piero Amodio; Jasmohan Bajaj; Juan Cordoba; Peter Ferenci; Kevin D Mullen; Karin Weissenborn; Philip Wong Journal: Hepatology Date: 2014-07-08 Impact factor: 17.425
Authors: Jasmohan S Bajaj; Leroy R Thacker; Douglas M Heuman; Richard K Sterling; R Todd Stravitz; Arun J Sanyal; Velimir Luketic; Michael Fuchs; Ho Chong S Gilles; James B Wade Journal: Liver Transpl Date: 2012-10 Impact factor: 5.799
Authors: Scott Mooney; Tarek I Hasssanein; Robin C Hilsabeck; Elizabeth A Ziegler; Meghan Carlson; Leeza M Maron; William Perry Journal: Arch Clin Neuropsychol Date: 2007-02-05 Impact factor: 2.813
Authors: Marsha Y Morgan; Piero Amodio; Nicola A Cook; Clive D Jackson; Gerald Kircheis; Mette M Lauridsen; Sara Montagnese; Sami Schiff; Karin Weissenborn Journal: Metab Brain Dis Date: 2015-09-28 Impact factor: 3.584
Authors: Krishnakant Saboo; Amirhossein Shamsaddini; Mihir V Iyer; Chang Hu; Andrew Fagan; Edith A Gavis; Melanie B White; Michael Fuchs; Douglas M Heuman; Masoumeh Sikaroodi; Ravishankar K Iyer; Patrick M Gillevet; Jasmohan S Bajaj Journal: J Hepatol Date: 2020-07-15 Impact factor: 25.083
Authors: Chathur Acharya; Omar Nadhem; Jawaid Shaw; Ramzi Hassouneh; Andrew Fagan; Sara McGeorge; Richard K Sterling; Puneet Puri; Michael Fuchs; Velimir Luketic; Arun J Sanyal; James B Wade; HoChong S Gilles; Douglas M Heuman; Felicia Tinsley; Scott Matherly; Hannah Lee; Mohammad S Siddiqui; Leroy R Thacker; Jasmohan S Bajaj Journal: Am J Gastroenterol Date: 2021-12-01 Impact factor: 10.864